Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Phathom Pharmaceuticals, Inc.PHAT · Entity 5177 | Chief Financial & Bus. Officer | October 06, 2026 | October 08, 2026 |
| Viatris IncVTRS · Entity 3277 | Chief Financial Officer | March 02, 2023 | March 07, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Phathom Pharmaceuticals, Inc.
Report date October 06, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 214,718 |
Reported balance
After 2026-10-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-06 · Tax withholding · Disposed 13,485 · Balance 214,718 F1: Represents shares underlying the restricted stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation. F2: Includes 1,488 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 1,123 |
Reported balance
Holding disclosure · report date 2026-10-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,123 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying the restricted stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.
F2: Includes 1,488 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2026.
Viatris Inc
Report date March 02, 2023 · Filed March 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 73,877 |
Ending reported balance
After 2023-03-04 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2023-03-02 · Exercise / conversion · Acquired 26,125 · Balance 61,299 Row 2 · 2023-03-02 · Tax withholding · Disposed 11,360 · Balance 49,939 F1: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on March 2, 2021. Row 3 · 2023-03-02 · Exercise / conversion · Acquired 2,067 · Balance 52,006 F2: Fractional shares have been rounded up in connection with the settlement described in footnote 9 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan. Row 4 · 2023-03-02 · Tax withholding · Disposed 899 · Balance 51,107 F3: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on March 2, 2021. Row 5 · 2023-03-04 · Exercise / conversion · Acquired 38,889 · Balance 89,996 Row 6 · 2023-03-04 · Tax withholding · Disposed 16,909 · Balance 73,087 F4: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the RSUs granted on March 4, 2022. Row 7 · 2023-03-04 · Exercise / conversion · Acquired 1,398 · Balance 74,485 F5: Fractional shares have been rounded up in connection with the settlement described in footnote 13 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan. Row 8 · 2023-03-04 · Tax withholding · Disposed 608 · Balance 73,877 F6: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the DEUs that accrued with respect to the RSUs previously granted on March 4, 2022. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 26,126 |
Reported balance
After 2023-03-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-03-02 · Exercise / conversion · Disposed 26,125 · Balance 26,126 F7: Each RSU represents the right to receive one share of common stock of Viatris Inc. (Viatris). 26,126 of the RSUs granted on March 2, 2021 vested on March 2, 2022, 26,125 vested on March 2, 2023 and 26,126 will vest on March 2, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 116,353 |
Reported balance
After 2023-03-03 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-03-03 · Grant · Acquired 116,353 · Balance 116,353 F10: Each RSU represents the right to receive one share of common stock of Viatris. 38,785 of the RSUs granted on March 3, 2023 will vest on March 3, 2024 and 38,784 will vest on each of March 3, 2025 and March 3, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 77,778 |
Reported balance
After 2023-03-04 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-03-04 · Exercise / conversion · Disposed 38,889 · Balance 77,778 F11: Each RSU represents the right to receive one share of common stock of Viatris. 38,889 of the RSUs granted on March 4, 2022 vested on March 4, 2023 and 38,889 will vest on each of March 4, 2024 and March 4, 2025. |
| Dividend Equivalent UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,066 |
Reported balance
After 2023-03-02 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-03-02 · Exercise / conversion · Disposed 2,066.3282 · Balance 2,066 F8: On May 6, 2022, Viatris filed a registration statement on Form S-3 with respect to its Dividend Reinvestment and Share Purchase Plan; amount includes DEUs that subsequently accrued with respect to such RSUs in June 2022, September 2022 and December 2022 in transactions exempt from Section 16 under Rule 16a-11. F9: Represents DEUs that accrued with respect to the RSUs previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. |
| Dividend Equivalent UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,796 |
Reported balance
After 2023-03-04 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2023-03-04 · Exercise / conversion · Disposed 1,397.7864 · Balance 2,796 F12: On May 6, 2022, Viatris filed a registration statement on Form S-3 with respect to its Dividend Reinvestment and Share Purchase Plan; amount represents DEUs that subsequently accrued with respect to such RSUs in June 2022, September 2022 and December 2022 in transactions exempt from Section 16 under Rule 16a-11. F13: Represents DEUs that accrued with respect to the RSUs previously granted on March 4, 2022 and vest on the same schedule as the underlying RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on March 2, 2021.
F2: Fractional shares have been rounded up in connection with the settlement described in footnote 9 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan.
F3: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on March 2, 2021.
F4: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the RSUs granted on March 4, 2022.
F5: Fractional shares have been rounded up in connection with the settlement described in footnote 13 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan.
F6: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the DEUs that accrued with respect to the RSUs previously granted on March 4, 2022.
F7: Each RSU represents the right to receive one share of common stock of Viatris Inc. (Viatris). 26,126 of the RSUs granted on March 2, 2021 vested on March 2, 2022, 26,125 vested on March 2, 2023 and 26,126 will vest on March 2, 2024.
F8: On May 6, 2022, Viatris filed a registration statement on Form S-3 with respect to its Dividend Reinvestment and Share Purchase Plan; amount includes DEUs that subsequently accrued with respect to such RSUs in June 2022, September 2022 and December 2022 in transactions exempt from Section 16 under Rule 16a-11.
F9: Represents DEUs that accrued with respect to the RSUs previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs.
F10: Each RSU represents the right to receive one share of common stock of Viatris. 38,785 of the RSUs granted on March 3, 2023 will vest on March 3, 2024 and 38,784 will vest on each of March 3, 2025 and March 3, 2026.
F11: Each RSU represents the right to receive one share of common stock of Viatris. 38,889 of the RSUs granted on March 4, 2022 vested on March 4, 2023 and 38,889 will vest on each of March 4, 2024 and March 4, 2025.
F12: On May 6, 2022, Viatris filed a registration statement on Form S-3 with respect to its Dividend Reinvestment and Share Purchase Plan; amount represents DEUs that subsequently accrued with respect to such RSUs in June 2022, September 2022 and December 2022 in transactions exempt from Section 16 under Rule 16a-11.
F13: Represents DEUs that accrued with respect to the RSUs previously granted on March 4, 2022 and vest on the same schedule as the underlying RSUs.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Intra-Cellular Therapies, Inc.
Report date April 02, 2025 · Filed April 02, 2025
Section 16 reporting ended · disclosed 2025-04-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $74.90 · Expires 2034-08-11 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-02 · Disposition to issuer · Disposed 17,251 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings. F3: (Continued from Footnote 2) Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediate-ly prior to the Effective Time, whether vested or unvested, and which had a per share ex-ercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-04-02 · Disposition to issuer · Disposed 35,046 · Balance 0 F5: Each restricted stock unit (each, a "Company RSU") represented a contingent right to re-ceive one Company Share. F6: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F7: Not applicable. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-04-02 · Disposition to issuer · Disposed 22,727 · Balance 0 F5: Each restricted stock unit (each, a "Company RSU") represented a contingent right to re-ceive one Company Share. F6: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F7: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time").
F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.
F3: (Continued from Footnote 2) Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediate-ly prior to the Effective Time, whether vested or unvested, and which had a per share ex-ercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.
F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration.
F5: Each restricted stock unit (each, a "Company RSU") represented a contingent right to re-ceive one Company Share.
F6: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances.
F7: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 8, 2026 21:44 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | Tax withholdingCommon Stock | 13,485 | $6.78 | $91,428.30 |
DisclosureSEC source: 0001193125-26-418114 · ownership.xml · nonDerivative · entry 1 Narula Sanjeev · CIK 0001820590 · Chief Financial & Bus. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,718 F1 · kind: Represents shares underlying the restricted stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation. F2 · balance_after: Includes 1,488 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2026. Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 17:42 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 42,848 | $0.00 Strike: $15.71 | $0.00 |
DisclosureSEC source: 0001193125-26-001123 · ownership.xml · derivative · entry 2 Narula Sanjeev · CIK 0001820590 · Chief Financial & Bus. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,848 Underlying: Common Stock · 42,848 shares Expires 2036-01-01 F2 · derivative.exercise_date: 1/48th of the total number of shares of common stock subject to the option vest monthly following the Vesting Commencement Date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 17:42 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 82,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-001123 · ownership.xml · nonDerivative · entry 1 Narula Sanjeev · CIK 0001820590 · Chief Financial & Bus. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,715 F1 · shares: Represents restricted stock units ("RSUs") granted on January 2, 2026. 1/3 of the total number of RSUs granted vest on each of the first three anniversaries of January 2, 2026, the vesting commencement date (the "Vesting Commencement Date"), subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| October 06, 2025 Filed Oct 7, 2025 17:25 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $11.61 | $0.00 |
DisclosureSEC source: 0001193125-25-233684 · ownership.xml · derivative · entry 1 Narula Sanjeev · CIK 0001820590 · Chief Financial & Bus. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2036-10-05 F1 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on October 6, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates. Read SEC document |
| October 06, 2025 Filed Oct 8, 2025 17:09 UTC Amendment | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 144,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-234650 · ownership.xml · nonDerivative · entry 1 Narula Sanjeev · CIK 0001820590 · Chief Financial & Bus. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,000 F1 · shares: Represents restricted stock units ("RSUs") granted on October 6, 2025. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of October 6, 2025, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2 · balance_after: This amendment is being filed to report the transaction which was inadvertently omitted in the Form 4 filed on behalf of the Reporting Person on October 7, 2025. Read SEC document |
| April 02, 2025 Filed Apr 2, 2025 17:30 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Disposition to issuerRestricted Stock Units · Derivative | 22,727 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-049592 · ownership.xml · derivative · entry 3 Narula Sanjeev · CIK 0001820590 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,727 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit (each, a "Company RSU") represented a contingent right to re-ceive one Company Share. F6 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F6 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F7 · derivative.expiration_date: Not applicable. Read SEC document |
| April 02, 2025 Filed Apr 2, 2025 17:30 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Disposition to issuerRestricted Stock Units · Derivative | 35,046 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-049592 · ownership.xml · derivative · entry 2 Narula Sanjeev · CIK 0001820590 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,046 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit (each, a "Company RSU") represented a contingent right to re-ceive one Company Share. F6 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F6 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F7 · derivative.expiration_date: Not applicable. Read SEC document |
| April 02, 2025 Filed Apr 2, 2025 17:30 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Disposition to issuerStock Option (right to buy) · Derivative | 17,251 | Not disclosed Strike: $74.90 | Not disclosed |
DisclosureSEC source: 0000950170-25-049592 · ownership.xml · derivative · entry 1 Narula Sanjeev · CIK 0001820590 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,251 shares Expires 2034-08-11 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). F2 · price: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings. F3 · price: (Continued from Footnote 2) Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediate-ly prior to the Effective Time, whether vested or unvested, and which had a per share ex-ercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4 · price: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). F2 · derivative.exercise_date: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings. F3 · derivative.exercise_date: (Continued from Footnote 2) Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediate-ly prior to the Effective Time, whether vested or unvested, and which had a per share ex-ercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4 · derivative.exercise_date: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 17:01 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantRestricted Stock Units · Derivative | 22,727 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-013670 · ownership.xml · derivative · entry 1 Narula Sanjeev · CIK 0001820590 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,727 Underlying: Common Stock · 22,727 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: On February 3, 2025, the reporting person was granted 22,727 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: On February 3, 2025, the reporting person was granted 22,727 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 18:01 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantRestricted Stock Units · Derivative | 35,046 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-097292 · ownership.xml · derivative · entry 2 Narula Sanjeev · CIK 0001820590 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,046 Underlying: Common Stock · 35,046 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: The restricted stock units vest as to one third of the shares on August 12, 2025, one third of the shares on August 12, 2026 and one third of the shares on August 12, 2027. F3 · derivative.expiration_date: The restricted stock units vest as to one third of the shares on August 12, 2025, one third of the shares on August 12, 2026 and one third of the shares on August 12, 2027. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 18:01 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantStock Option (right to buy) · Derivative | 17,251 | $0.00 Strike: $74.90 | $0.00 |
DisclosureSEC source: 0000950170-24-097292 · ownership.xml · derivative · entry 1 Narula Sanjeev · CIK 0001820590 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,251 Underlying: Common Stock · 17,251 shares Expires 2034-08-11 F1 · derivative.exercise_date: The option vests as to one third of the shares on August 12, 2025, one third of the shares on August 12, 2026 and one third of the shares on August 12, 2027. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 00:00 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionDividend Equivalent Units · Derivative | 1,397.7864 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007225 · doc4.xml · derivative · entry 13 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,796 Underlying: Common Stock · 1,397.7864 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · shares: On May 6, 2022, Viatris filed a registration statement on Form S-3 with respect to its Dividend Reinvestment and Share Purchase Plan; amount represents DEUs that subsequently accrued with respect to such RSUs in June 2022, September 2022 and December 2022 in transactions exempt from Section 16 under Rule 16a-11. F13 · derivative.exercise_date: Represents DEUs that accrued with respect to the RSUs previously granted on March 4, 2022 and vest on the same schedule as the underlying RSUs. F13 · derivative.expiration_date: Represents DEUs that accrued with respect to the RSUs previously granted on March 4, 2022 and vest on the same schedule as the underlying RSUs. F12 · balance_after: On May 6, 2022, Viatris filed a registration statement on Form S-3 with respect to its Dividend Reinvestment and Share Purchase Plan; amount represents DEUs that subsequently accrued with respect to such RSUs in June 2022, September 2022 and December 2022 in transactions exempt from Section 16 under Rule 16a-11. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 00:00 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionRestricted Stock Units · Derivative | 38,889 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007225 · doc4.xml · derivative · entry 12 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,778 Underlying: Common Stock · 38,889 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. 38,889 of the RSUs granted on March 4, 2022 vested on March 4, 2023 and 38,889 will vest on each of March 4, 2024 and March 4, 2025. F11 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. 38,889 of the RSUs granted on March 4, 2022 vested on March 4, 2023 and 38,889 will vest on each of March 4, 2024 and March 4, 2025. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 00:00 UTC | Viatris Inc VTRS · Entity 3277 | Tax withholdingCommon Stock | 608 | $11.13 | $6,767.04 |
DisclosureSEC source: 0000899243-23-007225 · doc4.xml · nonDerivative · entry 8 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,877 F6 · shares: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the DEUs that accrued with respect to the RSUs previously granted on March 4, 2022. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 00:00 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionCommon Stock | 1,398 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007225 · doc4.xml · nonDerivative · entry 7 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Fractional shares have been rounded up in connection with the settlement described in footnote 13 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 00:00 UTC | Viatris Inc VTRS · Entity 3277 | Tax withholdingCommon Stock | 16,909 | $11.13 | $188,197.17 |
DisclosureSEC source: 0000899243-23-007225 · doc4.xml · nonDerivative · entry 6 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,087 F4 · shares: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the RSUs granted on March 4, 2022. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 00:00 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionCommon Stock | 38,889 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007225 · doc4.xml · nonDerivative · entry 5 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 00:00 UTC | Viatris Inc VTRS · Entity 3277 | GrantRestricted Stock Units · Derivative | 116,353 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007225 · doc4.xml · derivative · entry 11 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,353 Underlying: Common Stock · 116,353 shares Expires not disclosed F10 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. 38,785 of the RSUs granted on March 3, 2023 will vest on March 3, 2024 and 38,784 will vest on each of March 3, 2025 and March 3, 2026. F10 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. 38,785 of the RSUs granted on March 3, 2023 will vest on March 3, 2024 and 38,784 will vest on each of March 3, 2025 and March 3, 2026. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 00:00 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionDividend Equivalent Units · Derivative | 2,066.3282 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007225 · doc4.xml · derivative · entry 10 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,066 Underlying: Common Stock · 2,066.3282 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · shares: On May 6, 2022, Viatris filed a registration statement on Form S-3 with respect to its Dividend Reinvestment and Share Purchase Plan; amount includes DEUs that subsequently accrued with respect to such RSUs in June 2022, September 2022 and December 2022 in transactions exempt from Section 16 under Rule 16a-11. F9 · derivative.exercise_date: Represents DEUs that accrued with respect to the RSUs previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. F9 · derivative.expiration_date: Represents DEUs that accrued with respect to the RSUs previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. F8 · balance_after: On May 6, 2022, Viatris filed a registration statement on Form S-3 with respect to its Dividend Reinvestment and Share Purchase Plan; amount includes DEUs that subsequently accrued with respect to such RSUs in June 2022, September 2022 and December 2022 in transactions exempt from Section 16 under Rule 16a-11. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 00:00 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionRestricted Stock Units · Derivative | 26,125 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007225 · doc4.xml · derivative · entry 9 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,126 Underlying: Common Stock · 26,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. (Viatris). 26,126 of the RSUs granted on March 2, 2021 vested on March 2, 2022, 26,125 vested on March 2, 2023 and 26,126 will vest on March 2, 2024. F7 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. (Viatris). 26,126 of the RSUs granted on March 2, 2021 vested on March 2, 2022, 26,125 vested on March 2, 2023 and 26,126 will vest on March 2, 2024. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 00:00 UTC | Viatris Inc VTRS · Entity 3277 | Tax withholdingCommon Stock | 899 | $11.13 | $10,005.87 |
DisclosureSEC source: 0000899243-23-007225 · doc4.xml · nonDerivative · entry 4 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,107 F3 · shares: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on March 2, 2021. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 00:00 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionCommon Stock | 2,067 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007225 · doc4.xml · nonDerivative · entry 3 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Fractional shares have been rounded up in connection with the settlement described in footnote 9 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 00:00 UTC | Viatris Inc VTRS · Entity 3277 | Tax withholdingCommon Stock | 11,360 | $11.13 | $126,436.80 |
DisclosureSEC source: 0000899243-23-007225 · doc4.xml · nonDerivative · entry 2 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,939 F1 · shares: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on March 2, 2021. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 00:00 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionCommon Stock | 26,125 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007225 · doc4.xml · nonDerivative · entry 1 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2023 Filed Mar 2, 2023 00:05 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionDividend Equivalent Units · Derivative | 1,549.9981 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-005642 · ownership.xml · derivative · entry 6 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,549.9981 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Represents DEUs that accrued with respect to the RSUs previously granted on November 20, 2020 and vested on the same schedule as the underlying RSUs. On May 6, 2022, Viatris filed a registration statement on Form S-3 with respect to its Dividend Reinvestment and Share Purchase Plan; amount includes DEUs that subsequently accrued with respect to such RSUs in June 2022, September 2022 and December 2022 in transactions exempt from Section 16 under Rule 16a-11. F5 · derivative.expiration_date: Represents DEUs that accrued with respect to the RSUs previously granted on November 20, 2020 and vested on the same schedule as the underlying RSUs. On May 6, 2022, Viatris filed a registration statement on Form S-3 with respect to its Dividend Reinvestment and Share Purchase Plan; amount includes DEUs that subsequently accrued with respect to such RSUs in June 2022, September 2022 and December 2022 in transactions exempt from Section 16 under Rule 16a-11. Read SEC document |
| February 27, 2023 Filed Mar 2, 2023 00:05 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionRestricted Stock Units · Derivative | 21,246 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-005642 · ownership.xml · derivative · entry 5 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,246 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. (Viatris). These RSUs vested in full on February 27, 2023. F4 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. (Viatris). These RSUs vested in full on February 27, 2023. Read SEC document |
| February 27, 2023 Filed Mar 2, 2023 00:05 UTC | Viatris Inc VTRS · Entity 3277 | Tax withholdingCommon Stock | 674 | $11.20 | $7,548.80 |
DisclosureSEC source: 0000950170-23-005642 · ownership.xml · nonDerivative · entry 4 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,174 F3 · shares: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of the dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on November 20, 2020. Read SEC document |
| February 27, 2023 Filed Mar 2, 2023 00:05 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionCommon Stock | 1,550 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-005642 · ownership.xml · nonDerivative · entry 3 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Fractional shares have been rounded up in connection with the settlement described in footnote 5 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan. Read SEC document |
| February 27, 2023 Filed Mar 2, 2023 00:05 UTC | Viatris Inc VTRS · Entity 3277 | Tax withholdingCommon Stock | 9,326 | $11.20 | $104,451.20 |
DisclosureSEC source: 0000950170-23-005642 · ownership.xml · nonDerivative · entry 2 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,298 F1 · shares: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of the restricted stock units (RSUs) granted on November 20, 2020. Read SEC document |
| February 27, 2023 Filed Mar 2, 2023 00:05 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionCommon Stock | 21,246 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-005642 · ownership.xml · nonDerivative · entry 1 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 23:01 UTC | Viatris Inc VTRS · Entity 3277 | GrantDividend Equivalent Units · Derivative | 926.8653 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-011987 · doc4.xml · derivative · entry 2 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,175.8653 Underlying: Common Stock · 926.8653 shares Expires not disclosed F2 · derivative.exercise_price: Represents DEUs that accrued with respect to RSUs previously granted on March 2, 2021 and vest on the same schedule as the remaining unvested RSUs. F2 · derivative.exercise_date: Represents DEUs that accrued with respect to RSUs previously granted on March 2, 2021 and vest on the same schedule as the remaining unvested RSUs. F2 · derivative.expiration_date: Represents DEUs that accrued with respect to RSUs previously granted on March 2, 2021 and vest on the same schedule as the remaining unvested RSUs. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 23:01 UTC | Viatris Inc VTRS · Entity 3277 | GrantDividend Equivalent Units · Derivative | 251.2463 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-011987 · doc4.xml · derivative · entry 1 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 758.9926 Underlying: Common Stock · 251.2463 shares Expires not disclosed F1 · derivative.exercise_price: Represents dividend equivalent units (DEUs) that accrued with respect to restricted stock units (RSUs) previously granted on November 20, 2020 and vest on the same schedule as the underlying RSUs. F1 · derivative.exercise_date: Represents dividend equivalent units (DEUs) that accrued with respect to restricted stock units (RSUs) previously granted on November 20, 2020 and vest on the same schedule as the underlying RSUs. F1 · derivative.expiration_date: Represents dividend equivalent units (DEUs) that accrued with respect to restricted stock units (RSUs) previously granted on November 20, 2020 and vest on the same schedule as the underlying RSUs. Read SEC document |
| March 04, 2022 Filed Mar 5, 2022 01:09 UTC | Viatris Inc VTRS · Entity 3277 | GrantRestricted Stock Units · Derivative | 116,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-009556 · doc4.xml · derivative · entry 7 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,667 Underlying: Common Stock · 116,667 shares Expires not disclosed F6 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs vest in three equal annual installments beginning on March 4, 2023. F6 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs vest in three equal annual installments beginning on March 4, 2023. Read SEC document |
| March 02, 2022 Filed Mar 5, 2022 01:09 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionDividend Equivalent Units · Derivative | 624.0882 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-009556 · doc4.xml · derivative · entry 6 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,249 Underlying: Common Stock · 624.0882 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Represents DEUs that accrued with respect to the RSUs previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. F5 · derivative.expiration_date: Represents DEUs that accrued with respect to the RSUs previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. Read SEC document |
| March 02, 2022 Filed Mar 5, 2022 01:09 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionRestricted Stock Units · Derivative | 26,126 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-009556 · doc4.xml · derivative · entry 5 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,251 Underlying: Common Stock · 26,126 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. (Viatris). 26,126 of the RSUs granted on March 2, 2021 vested on March 2, 2022, 26,125 will vest on March 2, 2023 and 26,126 will vest on March 2, 2024. F4 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. (Viatris). 26,126 of the RSUs granted on March 2, 2021 vested on March 2, 2022, 26,125 will vest on March 2, 2023 and 26,126 will vest on March 2, 2024. Read SEC document |
| March 02, 2022 Filed Mar 5, 2022 01:09 UTC | Viatris Inc VTRS · Entity 3277 | Tax withholdingCommon Stock | 272 | $10.48 | $2,850.56 |
DisclosureSEC source: 0000899243-22-009556 · doc4.xml · nonDerivative · entry 4 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,378 F3 · shares: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on March 2, 2021. Read SEC document |
| March 02, 2022 Filed Mar 5, 2022 01:09 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionCommon Stock | 625 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-009556 · doc4.xml · nonDerivative · entry 3 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Fractional shares have been rounded up in connection with the settlement described in footnote 5 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan. Read SEC document |
| March 02, 2022 Filed Mar 5, 2022 01:09 UTC | Viatris Inc VTRS · Entity 3277 | Tax withholdingCommon Stock | 11,415 | $10.48 | $119,629.20 |
DisclosureSEC source: 0000899243-22-009556 · doc4.xml · nonDerivative · entry 2 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,025 F1 · shares: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on March 2, 2021. Read SEC document |
| March 02, 2022 Filed Mar 5, 2022 01:09 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionCommon Stock | 26,126 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-009556 · doc4.xml · nonDerivative · entry 1 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 23:02 UTC | Viatris Inc VTRS · Entity 3277 | GrantDividend Equivalent Units · Derivative | 672.316 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-049652 · doc4.xml · derivative · entry 2 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,873.0882 Underlying: Common Stock · 672.316 shares Expires not disclosed F2 · derivative.exercise_price: Represents DEUs that accrued with respect to RSUs previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. F2 · derivative.exercise_date: Represents DEUs that accrued with respect to RSUs previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. F2 · derivative.expiration_date: Represents DEUs that accrued with respect to RSUs previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 23:02 UTC | Viatris Inc VTRS · Entity 3277 | GrantDividend Equivalent Units · Derivative | 182.2477 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-049652 · doc4.xml · derivative · entry 1 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 507.7463 Underlying: Common Stock · 182.2477 shares Expires not disclosed F1 · derivative.exercise_price: Represents dividend equivalent units ("DEUs") that accrued with respect to restricted stock units ("RSUs") previously granted on November 20, 2020 and vest on the same schedule as the underlying RSUs. F1 · derivative.exercise_date: Represents dividend equivalent units ("DEUs") that accrued with respect to restricted stock units ("RSUs") previously granted on November 20, 2020 and vest on the same schedule as the underlying RSUs. F1 · derivative.expiration_date: Represents dividend equivalent units ("DEUs") that accrued with respect to restricted stock units ("RSUs") previously granted on November 20, 2020 and vest on the same schedule as the underlying RSUs. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 22:00 UTC | Viatris Inc VTRS · Entity 3277 | GrantDividend Equivalent Units · Derivative | 634.3156 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-037650 · doc4.xml · derivative · entry 2 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200.7722 Underlying: Common Stock · 634.3156 shares Expires not disclosed F2 · derivative.exercise_price: Represents DEUs that accrued with respect to RSUs previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. F2 · derivative.exercise_date: Represents DEUs that accrued with respect to RSUs previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. F2 · derivative.expiration_date: Represents DEUs that accrued with respect to RSUs previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 22:00 UTC | Viatris Inc VTRS · Entity 3277 | GrantDividend Equivalent Units · Derivative | 171.9467 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-037650 · doc4.xml · derivative · entry 1 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325.4986 Underlying: Common Stock · 171.9467 shares Expires not disclosed F1 · derivative.exercise_price: Represents dividend equivalent units ("DEUs") that accrued with respect to restricted stock units ("RSUs") previously granted on November 20, 2020 and vest on the same schedule as the underlying RSUs. F1 · derivative.exercise_date: Represents dividend equivalent units ("DEUs") that accrued with respect to restricted stock units ("RSUs") previously granted on November 20, 2020 and vest on the same schedule as the underlying RSUs. F1 · derivative.expiration_date: Represents dividend equivalent units ("DEUs") that accrued with respect to restricted stock units ("RSUs") previously granted on November 20, 2020 and vest on the same schedule as the underlying RSUs. Read SEC document |
| June 21, 2021 Filed Jun 24, 2021 00:32 UTC | Viatris Inc VTRS · Entity 3277 | GrantDividend Equivalent Units · Derivative | 566.4566 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-025582 · doc4.xml · derivative · entry 2 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566.4566 Underlying: Common Stock · 566.4566 shares Expires not disclosed F2 · derivative.exercise_price: Represents DEUs that accrued with respect to RSUs previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. F2 · derivative.exercise_date: Represents DEUs that accrued with respect to RSUs previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. F2 · derivative.expiration_date: Represents DEUs that accrued with respect to RSUs previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. Read SEC document |
| June 21, 2021 Filed Jun 24, 2021 00:32 UTC | Viatris Inc VTRS · Entity 3277 | GrantDividend Equivalent Units · Derivative | 153.5519 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-025582 · doc4.xml · derivative · entry 1 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153.5519 Underlying: Common Stock · 153.5519 shares Expires not disclosed F1 · derivative.exercise_price: Represents dividend equivalent units ("DEUs") that accrued with respect to restricted stock units ("RSUs") previously granted on November 20, 2020 and vest on the same schedule as the underlying RSUs. F1 · derivative.exercise_date: Represents dividend equivalent units ("DEUs") that accrued with respect to restricted stock units ("RSUs") previously granted on November 20, 2020 and vest on the same schedule as the underlying RSUs. F1 · derivative.expiration_date: Represents dividend equivalent units ("DEUs") that accrued with respect to restricted stock units ("RSUs") previously granted on November 20, 2020 and vest on the same schedule as the underlying RSUs. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 23:36 UTC | Viatris Inc VTRS · Entity 3277 | GrantRestricted Stock Units · Derivative | 78,377 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009941 · doc4.xml · derivative · entry 1 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,377 Underlying: Common Stock · 78,377 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatris Inc. 26,126 of the RSUs will vest on March 2, 2022, 26,125 will vest on March 2, 2023 and 26,126 will vest on March 2, 2024. F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatris Inc. 26,126 of the RSUs will vest on March 2, 2022, 26,125 will vest on March 2, 2023 and 26,126 will vest on March 2, 2024. Read SEC document |
| November 20, 2020 Filed Nov 25, 2020 00:09 UTC | Viatris Inc VTRS · Entity 3277 | GrantRestricted Stock Units · Derivative | 21,246 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032087 · doc4.xml · derivative · entry 2 Narula Sanjeev · CIK 0001820590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,246 Underlying: Common Stock · 21,246 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock unit ("RSU") represents the right to receive one share of common stock of Viatris. The RSUs will vest on February 27, 2023. F2 · derivative.expiration_date: Each restricted stock unit ("RSU") represents the right to receive one share of common stock of Viatris. The RSUs will vest on February 27, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.